Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01870778 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 6,600
- Enrollment target
NCT01870778: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT01870778 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 6,600 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (755% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01870778, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 6,600 participants
- Enrollment target
Study Summary
The purpose of the study was to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.
Primary Outcome
The percentage of participants with an adjudicated CV death through day 180 was assessed.
Interventions
- DRUG Placebo
- DRUG RLX030
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,600 participants |
| Start Date | 2013-10-02 |
| Est. Completion | 2017-02-01 |
| Phase | Phase 3 |
What the finished NCT01870778 record still lists
NCT01870778 is an interventional study that assigns participants to a tested intervention. Its 6,600 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (755% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01870778 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01870778 about?
NCT01870778 is a clinical study titled "Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF". The purpose of the study was to evaluate the efficacy, safety and tolerability of intravenous infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.
What is the current status of trial NCT01870778?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 6,600 participants. The study started on 2013-10-02. Estimated completion is 2017-02-01.
What interventions are being tested in trial NCT01870778?
The interventions under investigation include: Placebo (DRUG), RLX030 (DRUG).
Who is sponsoring clinical trial NCT01870778?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01870778's enrollment target sits among peer trials
6,600 35th of 2000 higher than 1,966 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05143697 · 6,600 participants · NA
Motivational Wellness Coaching to Reduce Childhood Obesity in Families and Kids
- NCT05515224 · 6,600 participants · NA
5-Cog 2.0: A Pragmatic Clinical Trial
- NCT06272045 · 6,618 participants · NA
Early Intervention to Promote Cardiovascular Health of Mothers and Children
- NCT05369429 · 6,516 participants · NA
My Wellbeing Guide: a Novel Tool for Managing Stress and Improving Quality of Life
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI